首页> Urology> Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.

Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.

导出 LinkOut

翻译打印收藏纠错

第一作者： Saskia,de Groot

第一单位： Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

作者： Saskia,de Groot ^[1] ; William K,Redekop ^[1] ; Stefan,Sleijfer ^[2] ; Egbert,Oosterwijk ^[3] ; Axel,Bex ^[4] ; Lambertus A L M,Kiemeney ^[5] ; Carin A,Uyl-de Groot ^[6]

作者单位： Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. ^[1] Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. ^[2] Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Department of Urology, Nijmegen, The Netherlands. ^[3] Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[4] Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Department of Urology, Nijmegen, The Netherlands; Radboud Institute for Health Sciences, Radboud University Medical Center, Department for Health Evidence, Nijmegen, The Netherlands. ^[5] Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: degroot@imta.eur.nl. ^[6]